A pilot study assessing the relationship between plasma Galectin-3 levels and validated risk scores in PAH patients found that Galectin-3 levels increased progressively with higher risk strata according to the REVEAL 2.0 risk score. The gene discussed is LGALS3; the disease is pulmonary arterial hypertension.